Table 2 Survival Outcomes
Historical Controls N = 140 | 2nd line Ipilimumab N = 189 | |
|---|---|---|
Median follow-up months, (95% CI) | 30.4 (27.9–37.3) | 71.2 (70.3–116.5) |
1-year survival rates, (95% CI) | ||
Unadjusted | 17.1% (11–23%) | 34.3% (27–41%) |
IPTW-adjusted | 17.1% (11–23%) | 35.6% (27–43%) |
2-year survival rates, (95% CI) | ||
Unadjusted | 7.1% (2.9–11%) | 20.6% (15–27%) |
IPTW-adjusted | 7.1% (2.9–11%) | 21.1% (14–28%) |
3-year survival rates, (95% CI) | ||
Unadjusted | 4.7% (1.2–8.2%) | 15.2% (9.6–21%) |
IPTW-adjusted | 4.7% (1.2–8.2%) | 14.3% (8.0–21%) |